The paper presents data on demodicosis-induced blepharoconjunctivitis complicated by the dry eye, such as predictors, etiology, and pathogenesis of this disease. It gives a concise outline of the life history of mites and their species parasitizing on the human skin cycle and an extended treatment regimen for blepharoconjunctivitis complicated by the dry eye. The time course of changes in the pathological signs of blepharitis is shown when the latter is treated using the given regimen and the treatment is discontinued. The authors provide the data of Schirmer's test and Norn's test, which have been used to support the results of the present investigation. The mechanism of action of the drugs considered in the paper on the eyelids is outlined. There is a tendency for demodicosis-induced blepharoconjunctivitis to be completely eliminated and the signs of the dry eye to be compensated when meticulously chosen therapy, including hygienic measures, is performed.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Performance of a Toric, Monthly, Soft Contact Lens in Digital Device Users.
Clin Optom (Auckl)
January 2025
Research Department, Southern College of Optometry, Memphis, TN, USA.
Purpose: To determine the performance of TOTAL30 for Astigmatism (T30fA; Alcon; Fort Worth, TX, USA) contact lenses (CLs) in existing CL wearers who are also frequent digital device users.
Methods: This 1-month, 3-visit study recruited adult, 18- to 40-year-old subjects who were required to use daily digital devices for at least 8 hours per day. All subjects were refit into T30fA CLs.
Topical cyclosporine A in the management of dry eye disease in Sjögren's syndrome.
Reumatologia
December 2024
Department of Ophthalmology, Slovak Medical University and University Hospital in Bratislava, Slovakia.
The hypercapnic environment on the International Space Station (ISS): A potential contributing factor to ocular surface symptoms in astronauts.
Life Sci Space Res (Amst)
February 2025
Center for Space Medicine, Baylor College of Medicine, Houston, Texas, United States; Department of Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, Houston, Texas, United States; Departments of Ophthalmology, Neurology, and Neurosurgery, Weill Cornell Medicine, New York, New York, United States; Department of Ophthalmology, University of Texas Medical Branch, Galveston, Texas, United States; University of Texas MD Anderson Cancer Center, Houston, Texas, United States; Texas A&M College of Medicine, Texas, United States; Department of Ophthalmology, The University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States; The Houston Methodist Research Institute, Houston Methodist Hospital, Houston, Texas, United States.
With increasing advancements and efforts towards space exploration, there is a pressing need to understand the impacts of spaceflight on astronauts' health. Astronauts have reported signs and symptoms of dry eye disease upon traveling to the International Space Station (ISS), thus necessitating an evaluation of the factors that contribute to the onset of spaceflight associated dry eye disease. Prior literature describes the hypercapnic environment of the ISS; however, the link between the high CO levels and astronauts' symptoms of dry eye disease remains unexplored.
View Article and Find Full Text PDFEvaluation of dry eye parameters and meibomian gland function using the Lipiscan system in male androgenetic alopecia patients.
Clin Exp Optom
January 2025
Department of Ophthalmology, Giresun University, Giresun, Turkey.
Clinical Relevance: The prevalence of male androgenetic alopecia is increasing worldwide. Evaluation of dry eye parameters and meibomian glands of male androgenetic alopecia patients may help to better understand the effect of this disease on dry eye and to provide appropriate treatment for these patients.
Background: The aim of this work is to evaluate the relationship between male androgenetic alopecia, dry eye, and meibomian gland function.
1-Year real-world outcomes of faricimab in previously treated neovascular age-related macular degeneration.
Eye (Lond)
January 2025
Maidstone Hospital Eye Department, Hermitage Lane, Maidstone, UK.
Background And Objectives: Faricimab, a bispecific antibody targeting VEGF-A and angiopoietin-2, has shown promise in treating neovascular age-related macular degeneration (nAMD). This study evaluates 1-year outcomes of faricimab in treatment-experienced nAMD patients.
Methods: This single-centre retrospective cohort study included patients previously treated for nAMD who switched to faricimab between November 2022 and March 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!